[1]
|
Blaha, M.J. and Martin, S.S. (2013) How Do Statins Work? Changing Paradigms with Implications for Statin Allocation. Journal of the American College of Cardiology, 62, 2392-2394. https://doi.org/10.1016/j.jacc.2013.08.1626
|
[2]
|
Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E. and Lippman, S.M. (2005) Statins and Cancer Prevention. Nature Reviews Cancer, 5, 930-942. https://doi.org/10.1038/nrc1751
|
[3]
|
Pose, E., Trebicka, J., Mookerjee, R.P., Angeli, P. and Ginès, P. (2019) Statins: Old Drugs as New Therapy for Liver Diseases? Journal of Hepatology, 70, 194-202.
|
[4]
|
Adhyaru, B.B. and Jacobson, T.A. (2018) Safety and Efficacy of Statin Therapy. Nature Reviews Cardiology, 15, 757-769. https://doi.org/10.1038/s41569-018-0098-5
|
[5]
|
Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., Braun, L.T., de Ferranti, S., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1082-e1143. https://doi.org/10.1161/CIR.0000000000000700
|
[6]
|
Verpaalen, B., Neyts, J. and Delang, L. (2014) Are Statins a Viable Option for the Treatment of Infections with the Hepatitis C Virus? Antiviral Research, 105, 92-99. https://doi.org/10.1016/j.antiviral.2014.02.020
|
[7]
|
Delang, L., Paeshuyse, J., Vliegen, I., Leyssen, P., Obeid, S., Durantel, D., et al. (2009) Statins Potentiate the in Vitro Anti-Hepatitis C Virus Activity of Selective Hepatitis C Virus Inhibitors and Delay or Prevent Resistance Development. Hepatology, 50, 6-16. https://doi.org/10.1002/hep.22916
|
[8]
|
Kondo, C., Atsukawa, M., Tsubota, A., Itokawa, N., Fukuda, T., Matsu-shita, Y., et al. (2012) An Open-Label Randomized Controlled Study of Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C with versus without Fluvastatin. Journal of Viral Hepatitis, 19, 615-622. https://doi.org/10.1111/j.1365-2893.2011.01584.x
|
[9]
|
Butt, A.A., Yan, P., Bonilla, H., Abou-Samra, A.-B., Shaikh, O.S., Simon, T.G., et al. (2015) Effect of Addition of Statins to Antiviral Therapy in Hepatitis C Virus-Infected Persons: Results from ERCHIVES. Hepatology, 62, 365-374.
https://doi.org/10.1002/hep.27835
|
[10]
|
Bader, T., Fazili, J., Madhoun, M., Aston, C., Hughes, D., Rizvi, S., et al. (2008) Fluvastatin Inhibits Hepatitis C Replication in Humans. American Journal of Gastroenterology, 103, 1383-1389.
|
[11]
|
Drolz, A., Horvatits, T., Michl, B., Roedl, K., Schellongowski, P., Holzinger, U., et al. (2014) Statin Therapy Is Associated with Reduced Incidence of Hypoxic Hepatitis in Critically Ill Patients. Journal of Hepatology, 60, 1187-1193.
https://doi.org/10.1016/j.jhep.2014.01.019
|
[12]
|
Athyros, V.G., Katsiki, N., Karagiannis, A. and Mikhailidis, D.P. (2013) Statins and Nonalcoholic Fatty Liver Disease: A Bright Future? Expert Opinion on Investigational Drugs, 22, 1089-1093.
https://doi.org/10.1517/13543784.2013.824423
|
[13]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
|
[14]
|
Pockros, P.J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E.J., et al. (2019) CONTROL: A Randomized Phase 2 Study of Obeticholic Acid and Atorvastatin on Lipoproteins in Nonalcoholic Steatohepatitis Patients. Liver International, 39, 2082-2093. https://doi.org/10.1111/liv.14209
|
[15]
|
Dongiovanni, P., Petta, S., Mannisto, V., Margherita Mancina, R., Pipitone, R., Karja, V., et al. (2015) Statin Use and Non-Alcoholic Steatohepatitis in at Risk Individuals. Journal of Hepatology, 63, 705-12.
https://doi.org/10.1016/j.jhep.2015.05.006
|
[16]
|
Tsochatzis, E.A., Bosch, J. and Burroughs, A.K. (2014) Liver Cirrhosis. Lancet, 383, 1749-1761.
https://doi.org/10.1016/S0140-6736(14)60121-5
|
[17]
|
Bang, U.C., Benfield, T. and Bendtsen, F. (2017) Reduced Risk of Decompensation and Death Associated with Use of Statins in Patients with Alcoholic Cirrhosis. A Nationwide Case-Cohort Study. Alimentary Pharmacology & Therapeutics, 46, 673-680. https://doi.org/10.1111/apt.14243
|
[18]
|
Huang, Y.W., Lee, C.L., Yang, S.S., Fu, S.-C., Chen, Y.-Y., Wang, T.-C., et al. (2016) Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. American Journal of Gastroenterology, 111, 976-985. https://doi.org/10.1038/ajg.2016.179
|
[19]
|
Bishnu, S., Ahammed, S.M., Sarkar, A., Hembram, J., Chatterjee, S., Das, K., et al. (2018) Effects of Atorvastatin on Portal Hemodynamics and Clinical Outcomes in Patients with Cirrhosis with Portal Hypertension: A Proof-of-Concept Study. European Journal of Gastroenterology & Hepatology, 30, 54-59.
https://doi.org/10.1097/MEG.0000000000001006
|
[20]
|
Ajamieh, H., Farrell, G.C., McCuskey, R.S., Yu, J., Chu, E., Wong, H.-J., et al. (2015) Acute Atorvastatin Is Hepatoprotective against Ischaemia-Reperfusion Injury in Mice by Modulating eNOS and Microparticle Formation. Liver International, 35, 2174-2186. https://doi.org/10.1111/liv.12827
|
[21]
|
Cámara-Lemarroy, C.R., Guzmán-de la Garza, F.J., Alarcón-Galván, G., Cordero-Pérez, P., Muñoz-Espinosa, L., Torres-González, L., et al. (2014) Hepatic Ischemia/Reperfusion Injury Is Di-minished by Atorvastatin in Wistar Rats. Archives of Medical Research, 45, 210-216. https://doi.org/10.1016/j.arcmed.2014.02.001
|
[22]
|
Sarin, S., Kaman, L., Dahiya, D., Behera, A., Medhi, B. and Chawla, Y. (2016) Effects of Preoperative Statin on Liver Reperfusion Injury in Major Hepatic Resection: A Pilot Study. Updates in Surgery, 68, 191-197.
https://doi.org/10.1007/s13304-016-0370-3
|
[23]
|
Nabih, E.S. and El-Kharashi, O.A. (2019) Targeting HMGB1/TLR4 Axis and miR-21 by Rosuva Statin: Role in Alleviating Cholestatic Liver Injury in a Rat Model of Bile Duct Ligation. Naunyn-Schmiedeberg’s Archives of Pharmacology, 392, 37-43. https://doi.org/10.1007/s00210-018-1560-y
|
[24]
|
Cash, W.J., O’Neill, S., O’Donnell, M.E., McCance, D.R., Young, I.S., McEneny, J., et al. (2013) Randomized Controlled Trial Assessing the Effect of Simvastatin in Primary Bil-iary Cirrhosis. Liver International, 33, 1166-1174.
https://doi.org/10.1111/liv.12191
|
[25]
|
Kim, G. and Kang, E.S. (2019) Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. Seminars in Liver Disease, 39, 141-152. https://doi.org/10.1055/s-0039-1679956
|
[26]
|
Thrift, A.P., Natarajan, Y., Liu, Y. and El-Serag, H.B. (2019) Statin Use after Diagnosis of Hepatocellular Carcinoma Is Associated with Decreased Mortality. Clinical Gastroenterology and Hepatology, 17, 2117-2125.e3.
https://doi.org/10.1016/j.cgh.2018.12.046
|
[27]
|
Hsiang, J.C., Wong, G.L., Tse, Y.K., Wong, V.W.-S., Yip, T.C.-F. and Chan, H.L.-Y. (2015) Statin and the Risk of Hepatocellular Carcinoma and Death in a Hospital-Based Hepatitis B-Infected Population: A Propensity Score Landmark Analysis. Journal of Hepatology, 63, 1190-1197. https://doi.org/10.1016/j.jhep.2015.07.009
|
[28]
|
Tran, K.T., McMenamin, Ú.C., Coleman, H.G., Cardwell, C.R., Murchie, P., Iversen, L., et al. (2020) Statin Use and Risk of Liver Cancer: Evidence from Two Population-Based Stud-ies. International Journal of Cancer, 146, 1250-1260.
https://doi.org/10.1002/ijc.32426
|
[29]
|
Kim, G., Jang, S.Y., Nam, C.M. and Kang, E.S. (2018) Statin Use and the Risk of Hepatocellular Carcinoma in Patients at High Risk: A Nationwide Nested Case-Control Study. Journal of Hepa-tology, 68, 476-484.
|
[30]
|
Chiu, H.F., Ho, S.C., Chen, C.C. and Yang, C.-Y. (2011) Statin Use and the Risk of Liver Cancer: A Population-Based Case-Control Study. American Journal of Gastroenterology, 106, 894-898. https://doi.org/10.1016/j.jhep.2017.10.018
|
[31]
|
Shao, J.Y., Lee, F.P., Chang, C.L. and Wu, S.-Y. (2015) Statin-Based Palliative Therapy for Hepatocellular Carcinoma. Medicine, 94, e1801. https://doi.org/10.1097/MD.0000000000001801
|
[32]
|
蒋美纯, 朱萱. 他汀类药物治疗慢性肝病有效性及安全性研究进展[J]. 中国实用内科杂志, 2020, 40(5): 423-427.
|